282 related articles for article (PubMed ID: 24117499)
1. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
[TBL] [Abstract][Full Text] [Related]
2. Reduced αGlcNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett's adenocarcinoma, and pancreatic cancer.
Yamanoi K; Nakayama J
Histochem Cell Biol; 2018 Jun; 149(6):569-575. PubMed ID: 29658052
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of gastric gland mucin-specific glycan α1,4-linked N-acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach.
Yamanoi K; Sekine S; Higuchi K; Kushima R; Nakayama J
Histopathology; 2015 Dec; 67(6):898-904. PubMed ID: 25929994
[TBL] [Abstract][Full Text] [Related]
4. Intestinal metaplasia in Barrett's oesophagus may be an epiphenomenon rather than a preneoplastic condition, and CDX2-positive cardiac-type epithelium is associated with minute Barrett's tumour.
Watanabe G; Ajioka Y; Takeuchi M; Annenkov A; Kato T; Watanabe K; Tani Y; Ikegami K; Yokota Y; Fukuda M
Histopathology; 2015 Jan; 66(2):201-14. PubMed ID: 25040564
[TBL] [Abstract][Full Text] [Related]
5. Reduced gland mucin-specific O-glycan in gastric atrophy: A possible risk factor for differentiated-type adenocarcinoma of the stomach.
Yamada S; Okamura T; Kobayashi S; Tanaka E; Nakayama J
J Gastroenterol Hepatol; 2015 Oct; 30(10):1478-84. PubMed ID: 25967588
[TBL] [Abstract][Full Text] [Related]
6. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus.
Moons LM; Bax DA; Kuipers EJ; Van Dekken H; Haringsma J; Van Vliet AH; Siersema PD; Kusters JG
J Clin Pathol; 2004 Oct; 57(10):1063-8. PubMed ID: 15452161
[TBL] [Abstract][Full Text] [Related]
7. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
8. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Hayes S; Ahmed S; Clark P
J Clin Pathol; 2011 Feb; 64(2):110-3. PubMed ID: 21106545
[TBL] [Abstract][Full Text] [Related]
10. Diffuse MIST1 expression and decreased α1,4-linked N-acetylglucosamine (αGlcNAc) glycosylation on MUC6 are distinct hallmarks for gastric neoplasms showing oxyntic gland differentiation.
Yamada S; Yamanoi K; Sato Y; Nakayama J
Histopathology; 2020 Sep; 77(3):413-422. PubMed ID: 32502322
[TBL] [Abstract][Full Text] [Related]
11. Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.
Shiratsu K; Higuchi K; Nakayama J
Cancer Sci; 2014 Jan; 105(1):126-33. PubMed ID: 24138592
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
13. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
14. Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.
Ohya A; Yamanoi K; Shimojo H; Fujii C; Nakayama J
Cancer Sci; 2017 Sep; 108(9):1897-1902. PubMed ID: 28685935
[TBL] [Abstract][Full Text] [Related]
15. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
16. Decreased alpha-1,4-linked N-acetylglucosamine glycosylation in biliary tract cancer progression from biliary intraepithelial neoplasia to invasive adenocarcinoma.
Okumura M; Yamanoi K; Uehara T; Nakayama J
Cancer Sci; 2020 Dec; 111(12):4629-4635. PubMed ID: 33020993
[TBL] [Abstract][Full Text] [Related]
17. Campylobacter Concisus and Its Effect on the Expression of CDX1 and COX2.
Mozaffari Namin B; Soltan Dallal MM
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3211-3216. PubMed ID: 30486614
[TBL] [Abstract][Full Text] [Related]
18. Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Histopathology; 2013 Nov; 63(5):630-9. PubMed ID: 24004067
[TBL] [Abstract][Full Text] [Related]
19. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
20. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
